供体杀伤细胞免疫球蛋白样受体（KIR）单倍型B可改善多发性骨髓瘤异基因造血干细胞移植后的无进展生存期和总生存期。 - Suppr

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.

作者信息

Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübig T, Hilde-brandt Y, Atanackovic D, Alchalby H, Ayuk F, Zander A R, Bacher U, Eiermann T

出版信息

Leukemia. 2011 Oct;25(10):1657-61. doi: 10.1038/leu.2011.138. Epub 2011 Jun 7.

DOI:10.1038/leu.2011.138

PMID:21647155

Abstract

摘要

相似文献

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.供体杀伤细胞免疫球蛋白样受体（KIR）单倍型B可改善多发性骨髓瘤异基因造血干细胞移植后的无进展生存期和总生存期。

Leukemia. 2011 Oct;25(10):1657-61. doi: 10.1038/leu.2011.138. Epub 2011 Jun 7.

The impact of KIR2DS4 alleles and the expression of KIR in the development of acute GVHD after unrelated allogeneic hematopoietic SCT.KIR2DS4 等位基因及其表达对无关异基因造血干细胞移植后急性移植物抗宿主病发展的影响。

Bone Marrow Transplant. 2010 Sep;45(9):1435-41. doi: 10.1038/bmt.2009.357. Epub 2010 Jan 11.

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.自体/减低强度预处理异基因干细胞移植与骨髓瘤自体移植的比较：长期随访。

J Clin Oncol. 2011 Aug 1;29(22):3016-22. doi: 10.1200/JCO.2010.32.7312. Epub 2011 Jul 5.

Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.在多发性骨髓瘤患者中，与自体移植相比，异基因干细胞移植可降低疾病进展。

Bone Marrow Transplant. 2001 Apr;27(8):801-7. doi: 10.1038/sj.bmt.1703006.

KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation.KIR 基因和 KIR 配体影响无关供体、12/12 HLA 匹配的造血干细胞移植后急性移植物抗宿主病的发生。

Bone Marrow Transplant. 2009 Jul;44(2):97-103. doi: 10.1038/bmt.2008.432. Epub 2009 Jan 26.

Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.多发性骨髓瘤患者非清髓性异基因干细胞移植的单中心经验：诱导长期缓解

Neth J Med. 2007 May;65(5):178-84.

KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.KIR2DS5与慢性髓性白血病患者接受HLA相同干细胞移植后的无白血病生存期相关。

Mol Immunol. 2008 Aug;45(13):3631-8. doi: 10.1016/j.molimm.2008.04.016. Epub 2008 Jun 16.

Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.供体激活型杀伤细胞免疫球蛋白样受体（KIR）基因数量少而非KIR-配体错配可预防白血病患者在体内T细胞去除的非亲缘干细胞移植后复发并改善无病生存期。

Transplantation. 2006 Oct 27;82(8):1024-30. doi: 10.1097/01.tp.0000235859.24513.43.

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.国际骨髓瘤工作组关于异体干细胞移植治疗多发性骨髓瘤现状的共识声明。

J Clin Oncol. 2010 Oct 10;28(29):4521-30. doi: 10.1200/JCO.2010.29.7929. Epub 2010 Aug 9.

Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation.杀伤细胞免疫球蛋白样受体/HLA配型匹配对亲缘供体非清髓性异基因造血干细胞移植中T细胞完全供体嵌合体形成的影响

Bone Marrow Transplant. 2008 Apr;41(8):709-14. doi: 10.1038/sj.bmt.1705954. Epub 2008 Jan 14.

引用本文的文献

Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma.多发性骨髓瘤病程中自然杀伤细胞表型的改变

Cancers (Basel). 2021 Jan 10;13(2):226. doi: 10.3390/cancers13020226.

Allogeneic Transplantation in Multiple Myeloma-Does It Still Have a Place?异基因移植在多发性骨髓瘤中的应用——它仍有立足之地吗？

J Clin Med. 2020 Jul 10;9(7):2180. doi: 10.3390/jcm9072180.

Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance.影响干细胞移植后复发的一些生物学问题：T 细胞功能障碍、NK 细胞和内在肿瘤耐药性的作用。

Bone Marrow Transplant. 2018 Aug;53(8):949-959. doi: 10.1038/s41409-017-0078-0. Epub 2018 Jan 24.

Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle.骨髓瘤的同种异体移植：拼凑拼图碎片

Front Oncol. 2017 Dec 11;7:287. doi: 10.3389/fonc.2017.00287. eCollection 2017.

Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection.基于杀伤细胞免疫球蛋白样受体（KIR）的移植物选择降低无关供体干细胞移植后的复发率

Front Immunol. 2017 Feb 8;8:41. doi: 10.3389/fimmu.2017.00041. eCollection 2017.

Checkpoint inhibition in myeloma.骨髓瘤中的检查点抑制

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):528-533. doi: 10.1182/asheducation-2016.1.528.

Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing.杀伤细胞免疫球蛋白样受体（KIR）抑制性配体（HLA-I）的过表达决定了骨髓瘤的免疫监视依赖于多样且强大的自然杀伤（NK）细胞致敏。

Oncoimmunology. 2015 Oct 29;5(4):e1093721. doi: 10.1080/2162402X.2015.1093721. eCollection 2016 Apr.

Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia.急性髓系白血病非亲缘脐血移植中杀伤细胞免疫球蛋白样受体-配体匹配与预后

Biol Blood Marrow Transplant. 2016 Jul;22(7):1284-1289. doi: 10.1016/j.bbmt.2016.04.007. Epub 2016 Apr 16.

The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch.HLA-E限制的肽库的多样性解释了Arg107Gly错配的免疫学影响。

Immunogenetics. 2016 Jan;68(1):29-41. doi: 10.1007/s00251-015-0880-z. Epub 2015 Nov 9.

Human NK cells activated by EBV lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.由EBV淋巴母细胞激活的人自然杀伤细胞克服了血液癌细胞中抗凋亡的耐药机制。

Oncoimmunology. 2015 Jan 9;4(3):e991613. doi: 10.4161/2162402X.2014.991613. eCollection 2015 Mar.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.

作者信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献